Joseph J. Sacco

Clinical Senior Lecturer

University of Liverpool

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Medical Imaging Medical Imaging professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Joseph J. Sacco is a Clinical Senior Lecturer at the University of Liverpool in the United Kingdom. His research areas include advanced cancer therapies, immunotherapy, and methodologies for preclinical drug screening, particularly focusing on melanoma and mesothelioma. He has contributed to recent articles exploring the efficacy of novel cancer treatments and the development of patient-derived xenograft models.

Articles (19)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (21)

Ferhat Ay

Associate Professor

UNITED STATES

Joseph J. Sacco

Research Interests

Explore related searches

Contact this professor

About

Articles (19)

Meeting Report From the 2023 Cure Ocular Melanoma (<scp>CURE OM</scp>) Global Science Meeting, Philadelphia, <scp>PA</scp>, November 2023

RP1 Combined With Nivolumab in Advanced Anti–PD-1–Failed Melanoma (IGNYTE)

Methodology for generating chorioallantoic membrane patient-derived xenograft (CAM-PDX) models of pleural mesothelioma and performing preclinical imaging for the translation of cancer studies and drug screening.

Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer

Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma

A case of immunotherapy-induced thyroiditis

A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma

Correction: Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study(Ann Surg Oncol., (2024), 31, (5340–5351), 10.1245/s10434-024-15293-x)

Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study

Oestrogen Receptor Positive Metastatic Eccrine Porocarcinoma: A Case Report and Review of Anti-Oestrogen Therapy in Rare Cancers

Advances in the clinical management of uveal melanoma

Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma

Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs.

Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma

Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.

The Chick Embryo Xenograft Model for Malignant Pleural Mesothelioma: A Cost and Time Efficient 3Rs Model for Drug Target Evaluation

Adjuvant management of locally advanced oral squamous cell carcinoma – real-world challenges and opportunities

Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles

Cost-utility analysis of a decade of liver screening for metastases using the Liverpool Uveal Melanoma Prognosticator Online (LUMPO)

Collaborators (21)

Ferhat Ay

Mario Falchi

Klaus Okkenhaug

Sophie Papa

Leonie Taams

Martine J. Jager

Harish Poptani

Michael Onken

Rino Seedor

Bartosz Chmielowski

Marcus Butler

Roger Olofsson Bagge

Anthony M. Joshua

Simon Eschweiler

Paul Nathan

Judy M. Coulson

Antonio Eleuteri

Andrew E. Aplin

Paul Lorigan

Georgia Beasley

Andrew Schache

Make your next move.